Journal Scans
Sequential Treatment With Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD): The Prospective International Multicentre Phase 2 PTLD-1 Trial
R-CHOP in Post-Transplant Lymphoproliferative Disorder
R Trappe, S Oertel, V Leblond, S Choquet, et al
20111113
2011 Dec 13
Lancet Oncol
Sequential Treatment With Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD): The Prospective International Multicentre Phase 2 PTLD-1 Trial
Lancet Oncol. 2011 Dec 13;[Epub Ahead of Print], R Trappe, S Oertel, V Leblond, S Choquet, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Post-transplantation lymphoproliferative disorder (PTLD) develops in 1-10% of transplant recipients and can be Epstein-Barr virus (EBV) associated. To improve long-term efficacy after rituximab monotherapy and to avoid the toxic effects of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy seen in first-line treatment, we initiated a phase 2 trial to test whether the subsequent use of rituximab and CHOP would improve the outcome of patients with PTLD.Methods:...
